Cantargia Q4 2022: Progress in Triple-Negative Breast Cancer - Redeye

In the fourth quarter, Cantargia continued with its ongoing programs and strategy. The share price reached a historical low but has begun to recuperate since early January 2023. In February, after the end of Q4, solid efficacy results were presented from the phase I part of TRIFOUR in triple-negative breast cancer.

Länk till analysen i sin helhet: https://www.redeye.se/research/884305/cantargia-q4-2022-progress-in-triple-negative-breast-cancer?utm_source=finwire&utm_medium=RSS